The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis.

Cardiovasc Diabetol · 2024 · PMC10870515 · PMID 38360604

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0800

boldest claim

The sentences

marginally significantp = 0.05actually significant

Subgroup differences for the effect of SGLT2i on any-cause mortality in participants with HFpEF and HFrEF was marginally significant ( p = 0.05) (Supplemental Figure S18 ).

also in 26,082 other papers

marginally non-significantp = 0.08so close (0.05 < p ≤ 0.1)

Subgroup differences for the effect on kidney composite outcomes between SGLT2i and GLP-1RA as compared with standard care in participants with T2D was marginally non-significant ( p = 0.08) with a trend towards higher benefit for SGLT2i (Supplemental Figure S8 ).

also in 1,493 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.